Bob has served on Akoya Bioscience’s board since the company’s inception in 2015. Bob was a founder and served as a Managing Director of Telegraph Hill Partners (THP), a growth equity/late-stage venture capital investment firm focused exclusively on healthcare related companies, since its founding in 2001 until August 2020 when he became Partner Emeritus. Prior to THP, Bob was a principal in the investment firm of Mackowski & Shepler and an officer in the investment banking division of Merrill Lynch & Co. In addition to Akoya Biosciences, Bob currently serves on the boards of Agena Biosciences, Inc. and Dynex Technologies, Inc. Previously, Bob served on the boards of Kinetikos Medical (acquired by Integra), AcroMetrix, Inc. (acquired by Life Technologies), Aurora Discovery, Inc. (acquired by NEXUS Biosystems), Applied Precision (acquired by GE), LDR Holding Corporation (NASDAQ:LDRH), Endoscopic Technologies, Inc. (acquired by AtriCure), Sage Labs, Inc. (acquired by Horizon Discovery), Vidacare Corporation (acquired by Teleflex), ReloAction, Inc. (acquired by Hewitt Associates), Microinterventional Systems, Inc. (acquired by Medtronic), Reading Glass Company, Inc., One Body, Inc., R.D. Percy & Company, RareCyte, Inc. and was chairman of Genomics Solutions, Inc. (NASDAQ: GNSL). He also was a board observer at Magstim, Inc. and Precision Nanosystems, Inc. (acquired by Danaher). Bob received a BA from Duke University and an MBA from New York University.
How do I contact Robert G. Shepler?
Has Robert G. Shepler been buying or selling shares of Akoya Biosciences?
Robert G. Shepler has not been actively trading shares of Akoya Biosciences in the last ninety days. Most recently, on Thursday, November 18th, Robert G. Shepler bought 35,000 shares of Akoya Biosciences stock. The stock was acquired at an average cost of $12.60 per share, with a total value of $441,000.00. Learn More on Robert G. Shepler's trading history.
Who are Akoya Biosciences' active insiders?
Are insiders buying or selling shares of Akoya Biosciences?
In the last twelve months, Akoya Biosciences insiders bought shares 3 times. They purchased a total of 243,388 shares worth more than $1,208,940.00. In the last twelve months, insiders at the sold shares 4 times. They sold a total of 27,500 shares worth more than $136,475.00. The most recent insider tranaction occured on March, 20th when CEO Brian Mckelligon sold 7,500 shares worth more than $37,275.00. Insiders at Akoya Biosciences own 8.5% of the company.
Learn More about insider trades at Akoya Biosciences. Information on this page was last updated on 3/20/2024.
